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I. EXTENDED ABSTRACT
One of the missions of Precision Medicine (PM) is to tackle
the issue of interpreting the mass of malignant cells or tumor
nature to design the most appropriate strategy to treat patients
[1], [2]. To this extent, recent therapies focus on the tumor
microenvironment (TME) and, more specifically, on the role
of the immune cells in it [3]. Such treatments take advantage
of the intrinsic properties of the immune system: malignant
cells are recognized as a pathogen and in turn will be utterly
destroyed [4]. Therefore, successful-to-thrive tumor means that
cancer cells are evading immunological attacks among other
anti-tumoral mechanisms.
The field of PM has made progress thanks to the evolution
of the concept of disease. By leaving behind the application
of one-layered approach studies, diseases are now understood
as an interconnected and multidimensional multilayerered net-
work of molecular mechanisms of biological processes [1], [5].
Particularly, Cancer disease was traditionally explained as the
aftereffect of somatic mutations of cancer related genes [6],
[7], [8]. Actually, most typical cancer-associated driver genes
such TP53 or BRCA2 are usually found mutated in tumors
[6], [7], [8] as they happen to be key regulators of cell death
processes [9], [10]. However scientific studies solely based on
isolated mutations produced on these type of genes are not able
to explain nor predict the whole process and development of
the disease [11].
In a further complication, every tumor is unique [12]. This
is due to the convoluted relationship existing between cellular
processes such as genetic and epigenetic modifications that
may alter the intracellular and extracellular composition and,
by extension, the TME [13]. For instance, results obtained by
The Cancer Genome Atlas (TCGA) from the transcriptional
analysis of 10,000 tumor samples from different subjects and
33 different types of cancer pointed out the existing variation
of immune cells population across tumors (Figure 1) [14].
Against the general tendency to study the effect of cancer-
associated somatic mutations on a genetic level, the present
work pays attention to their impact from a structural point of
view in the TME. Clearly, it is not the same to find a mutation
affecting the catalytic site of a protein than in a non-functional
area of the structure [15], [16]. The goal is to analyze the
Biology underlying variation on the tumor immune infiltration
and to what degree this can be explained by the location of
missense mutations on the protein structure. More specifically,
major emphasis has been put on the mutation occurring on the
interaction or interface area of these proteins.
A. Methods
We hypothesized that all protein residues involved in the
same interface create a functional region within a protein.
Mutations within the same functional region are more likely
to have the same effect than mutations in different functional
regions. To identify such interfaces, we analyzed 421582 pro-
tein coordinate files from the Protein Data Bank. We defined
protein interfaces as all the residues in close proximity to
either other proteins, nucleic acids or small ligands. We then
generated used a linear model to analyze 1839298 missense
somatic mutations from 10224 patients from The Cancer
Genome Atlas:
Leukocyte fractioni = β0
+ β1Cancer Typei
+ β2Tumor Mutation Burdeni
+ β3Mutation 3D Locationi
+ β4Biological Sexi
+ 5
with i = 1, ... , n; being n the total number of TCGA
patients.
B. Results
We generated a catalogue of 145046 protein interfaces
(52237 protein-protein, 5329 protein-nucleic acid and 87480
protein-ligand). Our preliminary results show that 13379 of
these interfaces, when somatically mutated, correlate with
changes in the quantity of the immune infiltrate in the tumor
microenvironment.
For example, mutations on the interface between pep-
tidylarginine deiminase 1 (PAD1) and Ca2+ atoms, which
correspond to the catalytic site of the enzyme, were found
in patients with higher levels of immune infiltrate than cancer
patients with other mutations in the same gene or no mutations
in the gene at all. Interestingly, PAD1 is in charge of protein
citrullination since it converts arginine to citrulline, being these
citrullinated proteins target of antibodies [ref]. Perhaps, in
these patients, if the levels of citrulline is low due to the
mutation on the catalytic site, less number of citrullinated
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Fig. 1. Distribution of leukocyte fraction (synonym of immune infiltrate) across the different TCGA samples. Each dot corresponds to an individual tumor
sample and the samples are grouped according to the Cancer type classification. Box-plots summarize each sex contributions to the leukocyte fraction distribution.
proteins will be found and lead to lower immune attack to
the cancer cell.
C. Future work
Next steps will focus on the global study of all the
mutations of the protein interfaces. It would be interesting to
be able to discriminate which mutations have higher effects
and why, in terms of tumor immune-infiltrate. Moreover, linear
models will be cross-validated to rise the statistical power of
the results.
REFERENCES
[1] K. Matchett, N. Lynam-Lennon, R. Watson, and J. Brown, “Advances
in Precision Medicine: Tailoring Individualized Therapies,” Cancers,
vol. 9, no. 12, p. 146, oct 2017.
[2] G. Bindea, B. Mlecnik, H. K. Angell, and J. Galon, “The immune
landscape of human tumors: Implications for cancer immunotherapy.”
Oncoimmunology, vol. 3, no. 1, p. e27456, jan 2014.
[3] M. Binnewies, E. W. Roberts, K. Kersten, V. Chan, D. F. Fearon,
M. Merad, L. M. Coussens, D. I. Gabrilovich, S. Ostrand-Rosenberg,
C. C. Hedrick, R. H. Vonderheide, M. J. Pittet, R. K. Jain, W. Zou,
T. K. Howcroft, E. C. Woodhouse, R. A. Weinberg, and M. F. Krum-
mel, “Understanding the tumor immune microenvironment (TIME) for
effective therapy,” Nature Medicine, vol. 24, no. 5, pp. 541–550, may
2018.
[4] C. L. Ventola, “Cancer Immunotherapy, Part 1: Current Strategies and
Agents.” P & T : a peer-reviewed journal for formulary management,
vol. 42, no. 6, pp. 375–383, jun 2017.
[5] L. J. Frey, “Data integration strategies for predictive analytics in
precision medicine,” Personalized Medicine, vol. 15, no. 6, pp. 543–
551, nov 2018.
[6] L. Luzzatto, “Somatic mutations in cancer development,” Environmental
Health, vol. 10, no. Suppl 1, p. S12, 2011.
[7] L. R. Yates and P. J. Campbell, “Evolution of the cancer genome,”
Nature Reviews Genetics, vol. 13, no. 11, pp. 795–806, nov 2012.
[8] I. R. Watson, K. Takahashi, P. A. Futreal, and L. Chin, “Emerging
patterns of somatic mutations in cancer,” Nature Reviews Genetics,
vol. 14, no. 10, pp. 703–718, oct 2013.
[9] E. R. Kastenhuber and S. W. Lowe, “Putting p53 in Context.” Cell, vol.
170, no. 6, pp. 1062–1078, sep 2017.
[10] R. Roy, J. Chun, and S. N. Powell, “BRCA1 and BRCA2: different
roles in a common pathway of genome protection,” Nature Reviews
Cancer, vol. 12, no. 1, pp. 68–78, jan 2012.
[11] K. M. Coyle, J. E. Boudreau, and P. Marcato, “Genetic Mutations
and Epigenetic Modifications: Driving Cancer and Informing Precision
Medicine,” BioMed Research International, vol. 2017, pp. 1–18, 2017.
[12] R. J. Hartmaier, J. Charo, D. Fabrizio, M. E. Goldberg, L. A. Albacker,
W. Pao, and J. Chmielecki, “Genomic analysis of 63,220 tumors reveals
insights into tumor uniqueness and targeted cancer immunotherapy
strategies,” Genome Medicine, vol. 9, no. 1, p. 16, dec 2017.
[13] F. Petitprez, C.-M. Sun, L. Lacroix, C. Saute`s-Fridman, A. de Reynie`s,
and W. H. Fridman, “Quantitative Analyses of the Tumor Microenviron-
ment Composition and Orientation in the Era of Precision Medicine,”
Frontiers in Oncology, vol. 8, sep 2018.
[14] V. Thorsson, D. L. Gibbs, and E. Al., “The Immune Landscape of
Cancer,” Immunity, vol. 48, no. 4, pp. 812–830.e14, apr 2018.
[15] J. Ashworth, B. Bernard, S. Reynolds, C. L. Plaisier, I. Shmulevich,
and N. S. Baliga, “Structure-based predictions broadly link transcription
factor mutations to gene expression changes in cancers,” Nucleic Acids
Research, vol. 42, no. 21, pp. 12 973–12 983, dec 2014.
[16] S. Khan and M. Vihinen, “Spectrum of disease-causing mutations in
protein secondary structures,” BMC Structural Biology, vol. 7, no. 1,
p. 56, 2007.
Victoria Ruiz-Serra received his BSc degree in
Biochemistry from University of Seville in 2014. The
following 2 years, she worked at the Biochemistry
and Molecular Biology department of the Faculty of
Pharmacy at the University of Seville. She completed
his MSc degree in Bioinformatics from Vrije Univer-
sity and Amsterdam University, The Netherlands in
2018. Since 2018, she is a PhD student in the Life
Science group of Barcelona Supercomputing Center
(BSC), Spain.
6th BSC Severo Ochoa Doctoral Symposium
99
